// App-Quantinova.ai

TPS3095 : A phase 1, first-time-in-human study of MEDI9197, a TLR7/8 agonist, administered intratumorally in subjects with a solid tumor cancer.

Researchers

Presenter

  • Shilpa Gupta

Principal Investigators

  • Fatemeh Tavakkoli

  • Serguei Soukharev

  • Guozhi Gao

  • Shannon R. Morris

  • Jeffrey S Miller

Medical Centers

  • Masonic Cancer Center, University of Minnesota, Minneapolis, MN

  • MedImmune, Gaithersburg, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02556463

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved